Nina Bhardwaj, M.D., Ph.D., is an immunologist who has made seminal contributions to human dendritic cell biology, specifically with respect to their isolation, biology, antigen presenting function, and use as vaccine adjuvants in humans. She is the director of immunotherapy at the Icahn School of Medicine at Mount Sinai and holds the Ward Coleman Chair in Cancer Research. Bhardwaj brings expertise in human immunology and a variety of immune therapies, having developed toll-like receptor agonist based and dendritic cell based vaccines for the treatment of both cancer and infection in several investigator initiated studies.
Bhardwaj is an elected member of the American Society of Clinical Investigation and the Association of American Physicians, a recipient of the Doris Duke Distinguished Scientist Award, and was named one of Scientific American Magazine’s top 50 researchers, receiving the award for Medical Research in 2004. She received the Fred W. Alt Award for new discoveries in Immunology in 2015 from The Cancer Research Institute. Bhardwaj also is a senior editor of the American Association for Cancer Research’s Cancer Immunology Research journal, senior editor for Frontiers in Immunology and consulting editor for the Journal of Clinical Investigation. She has served on the National Institutes of Health’s Study Sections and multiple advisory councils. Bhardwaj was a previous chair of the Cancer Immunology Steering Committee of the American Association for Cancer Research. She has authored more than 180 publications.